A Study of GlcNAc on Tear Production in NGLY1-CDDG

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

NGLY1 Deficiency

Interventions

DRUG

GlcNAc-GlcN

GlcNAc powder - weight-dependent dose

OTHER

Placebo

Placebo xylose

Trial Locations (2)

Children's Hospital of Philadelphia, Philadelphia

Seattle Children's Hospital, Seattle

All Listed Sponsors

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Seattle Children's Hospital

OTHER

lead

Eva Morava-Kozicz

OTHER

NCT05402345 - A Study of GlcNAc on Tear Production in NGLY1-CDDG | Biotech Hunter | Biotech Hunter